This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Device Based Therapy in Hypertension Trial (DEBuT-HT)

This study has been completed.
Information provided by (Responsible Party):
CVRx, Inc. Identifier:
First received: July 1, 2008
Last updated: October 19, 2016
Last verified: October 2016
The purpose of this study is to demonstrate the safety and efficacy of the Rheos Baroreflex Hypertension Therapy System in patients with refractory hypertension.

Condition Intervention
Hypertension Device: Rheos Baroreflex Hypertension Therapy System

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study of Baroreflex Hypertension Therapy in Refractory Hypertension

Further study details as provided by CVRx, Inc.:

Primary Outcome Measures:
  • Demonstrate the safety of Rheos(TM) Baroreflex Hypertension Therapy (TM) System by evaluating all adverse events and estimating the system and procedure related adverse event rate. [ Time Frame: 4 months post implant ]
  • Demonstrate a 10 mmHg decrease from baseline (1-Month office cuff blood pressure) in systolic blood pressure after three months of incrementally optimized therapy. [ Time Frame: 4 months post implant ]

Enrollment: 46
Study Start Date: July 2003
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Rheos Implant Device: Rheos Baroreflex Hypertension Therapy System
This therapy uses implantable device-based electrical activation of the carotid sinus baroreflex to control blood pressure.

Detailed Description:
The DEBuT-HT trial will investigate the safety and efficacy of Rheos Baroreflex Hypertension Therapy(TM) in patients with refractory hypertension despite full pharmacologic therapy. Enrolled patients will be carefully assessed prior to receiving a permanently implanted Rheos System. Once the system is implanted, these patients will be followed closely for 1 month to establish baseline information. The Rheos System will be programmed "ON" at the 1 month follow-up and incrementally increased at 2 and 3-month follow-up evaluations. An assessment of safety and efficacy will be made at the 4-month follow-up. Enrolled patients will be followed annually thereafter.

Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Be at least 21 years of age.
  • Have been assessed to have bilateral carotid bifurcations located at or below C3 - C4.
  • Have blood pressure greater than or equal to 160 mmHg systolic and/or greater than or equal to 90 mmHg diastolic despite at least two months of full therapy with at least three (3) anti-hypertensive medications, of which at least one (1) must be a diuretic.
  • Must be certified by the investigator as compliant to taking full doses of medications.
  • Have signed an approved informed consent form for participation in this study.

Exclusion Criteria:

  • Have been diagnosed with:

    • Baroreflex failure or significant orthostatic hypotension
    • Cardiac brady arrhythmias or chronic atrial fibrillation
  • Have carotid atherosclerosis determined by ultrasound or angiographic evaluation with a stenosis of greater than 50%.
  • Have prior surgery or radiation in either carotid sinus region
  • Currently have implanted electrical medical devices such as cardiac pacing, defibrillation or neurologic stimulation systems.
  • Are pregnant or contemplating pregnancy during the 4-month follow-up period.
  • Are on dialysis
  • Have hypertension secondary to a treatable cause
  • Have clinically significant cardiac valvular disease
  • Are unable to comply with protocol requirements.
  • Are unlikely to survive the protocol follow-up period
  • Are enrolled in another concurrent clinical trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00710190

Czech Republic
University Hospital Hradec Kralove
Hradec Kralove, Czech Republic
University Hospital Bad Oeynhausen
Bad Oeynhausen, Germany
Charité Campus Buch
Berlin, Germany
Uniklinik Essen
Essen, Germany
University Hospital Hannover
Hannover, Germany
Latvian Centre of Cardiology
Riga, Latvia
Academisch Ziekenhuis Maastricht
Maastricht, Netherlands
Medical University of Gdansk
Gdansk, Poland
Inselspital Bern
Bern, Switzerland
Sponsors and Collaborators
CVRx, Inc.
Study Director: Thomas Baal, PhD CVRx, Inc.
  More Information

Additional Information:
Responsible Party: CVRx, Inc. Identifier: NCT00710190     History of Changes
Other Study ID Numbers: 360004-001
Study First Received: July 1, 2008
Last Updated: October 19, 2016

Keywords provided by CVRx, Inc.:
Drug Resistant Hypertension
Refractory Hypertension
High Blood Pressure
Baroreflex Hypertension Therapy

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases processed this record on September 25, 2017